In the high-stakes world of biopharmaceutical development, timing, precision, and regulatory alignment often determine whether a program advances or stalls. For AEON Biopharma Inc. (AEON), the final stretch of 2025 is shaping up to be a pivotal chapter, one that could either validate years of groundwork or demand a strategic reset.
A Critical Meeting on the Horizon
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com